Acelink Therapeutics

San Francisco, United States · Founded 2019 · $800K raised

Employees
1–10
Founded
2019
Business Model
B2B
Total Funding
$800K
Last Round
$800K Seed
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

AceLink Therapeutics is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in the San Francisco Bay Area, focused on developing first-in-class therapies for rare genetic diseases driven by glycolipid biology. The company's lead programs include AL1211, a GCS inhibitor in Phase 2 trials for Fabry disease and Type I Gaucher disease; AL0804, a brain-penetrant GCS inhibitor targeting neuronopathic glycolipid storage diseases; and AL1311, an NRF2 activator for autosomal dominant polycystic kidney disease (ADPKD). AceLink leverages a lean, outsourced development model, collaborating with CROs, academic partners, and key opinion leaders to efficiently translate scientific discoveries into medicines. Its customers are patients and healthcare providers treating rare inherited metabolic and renal diseases.

Summary

Acelink Therapeutics is a Biotech company based in San Francisco, United States, founded in 2019. It has raised $800K in total across 1 round. Investors include Kaitai Capital.

Tech & App Stack

Funding History

SeedSeed Round
$800K

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Acelink Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/acelink-therapeutics"><img src="https://indexed.vc/api/badge/company/acelink-therapeutics" alt="Acelink Therapeutics on Indexed.vc" width="260" height="76" /></a>